InvestSMART

Acrux Limited (ASX:ACR)

ALERT: Price-sensitive ASX Announcement for ACR
Current share price for ACR : $0.012 -0.001 (-4.17%)+
Announcement
Release
29 May 2026 12:19PM
Price at Release
$0.012
Full Release
download
Summary
Acrux Limited announced the licensing of Lenzetto® for the Australian market with a total value of milestones up to AUD 5.4 million. The agreement includes an upfront signing milestone payable 14 days after the execution of the amendment. The second regulatory milestone is tied to achieving marketing authorisation from the Therapeutic Goods Authority in Australia, for which Gedeon Richter Plc is responsible. The third and final commercial milestone is triggered by either reaching a cumulative sales target or the second anniversary post-launch. This strategic move is aimed at enhancing Acrux's pharmaceutical presence in Australia.
Key Points
  • Licensing of Lenzetto® for Australia for AUD 5.4 million.
  • First payment is an upfront signing milestone due in 14 days.
  • Second milestone tied to obtaining TGA marketing authorisation.
  • Gedeon Richter Plc responsible for Lenzetto® registration in Australia.
  • Final milestone based on sales target or two-year post-launch.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.